Following the science to improve patient outcomes

What will make the biggest difference?

Recent developments in the understanding of respiratory disease pathways mean that we are entering an era of unprecedented potential to deliver scientific breakthroughs and transform the lives of people with asthma and COPD. Our 40-year heritage in respiratory science is just the beginning of our story. Hear more from the people at AstraZeneca behind our commitment to respiratory disease.

Veeva ID: Z4-4823    Date of expiry: 22/05/2018

Whether you’re a bench scientist, whether you’re in commercial, whether you’re in development, it’s taking great ideas, innovative science and translating them into medicines that are going to make a transformational difference to patients. That’s what drives us, and that’s what science can do.

Tom Keith-Roach Vice-President, Respiratory

Veeva ID: Z4-4823    Date of expiry: 22/05/2018

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Respiratory (as at 2 February 2018)

Phase 1

Phase 1

  • AZD1402 asthma
  • AZD5634 cystic fibrosis
  • AZD7594 + abediterol asthma/chronic obstructive pulmonary disease
  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • AZD1419 asthma
  • AZD7594 asthma/chronic obstructive pulmonary disease
  • AZD7986 chronic obstructive pulmonary disease
  • AZD8871 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • PT010 asthma
  • abediterol asthma/chronic obstructive pulmonary disease
  • tezepelumab atopic dermatitis

Phase 3

Phase 3

  • Bevespi Aerosphere PINNACLE chronic obstructive pulmonary disease
  • Fasenra (benralizumab) CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • PT010 chronic obstructive pulmonary disease
  • tezepelumab NAVIGATOR SOURCE severe, uncontrolled asthma

LCM Projects

LCM Projects

  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra (benralizumab) TERRANOVA GALATHEA chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

Our medicines

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations.

You should visit your local AstraZeneca site to find out more about our medicines in your country. In some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.

  • Accolate, Accoleit, Vanticon zafirlukast
  • Bricanyl Respules terbutaline
  • Bricanyl Turbuhaler terbutaline in a dry powder inhaler
  • Daliresp/Daxas roflumilast
  • Duaklir Genuair aclidinium/formoterol
  • Eklira Genuair/Tudorza/Bretaris aclidinium, a LAMA
  • Fasenra benralizumab
  • Oxis Turbuhaler Oxis Turbuhaler
  • Pulmicort Turbuhaler budesonide
  • Pulmicort Respules budesonide inhalation suspension
  • Rhinocort budesonide
  • Symbicort pMDI budesonide/formoterol
  • Symbicort Turbuhaler budesonide/formoterol

Commitment to science

Our commitment to science is reflected in our track record of publications. View recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Our resources

Our focus on unmet medical needs

Improving patient outcomes with tailored therapies, devices, and support tools

  • Global burden of respiratory diseases

    Raising awareness of the ongoing unmet medical need in asthma, COPD and idiopathic pulmonary fibrosis (IPF)

  • Inhaled therapies and novel combinations

    Optimising our portfolio of inhaled medicines to improve choice and outcomes for patients across the disease spectrum

  • Targeted biologic therapies

    Using new scientific insights about the biology of respiratory diseases and patient phenotypes to create targeted biologic therapies

Partnering case studies

Veeva ID: Z4-4823    Date of expiry: 22/05/2018

Veeva ID: Z4-4823
Date of prep: 22/05/2017
Date of expiry: 22/05/2018